305OOverall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Emens, L A, Esteva, F J, Beresford, M, Saura, C, De Laurentiis, M, Kim, S-B, Im, S-A, Wang, Y, Mani, A, Shah, J, Liu, H, de Haas, S, Patre, M, Loi, SVolume:
30
Langue:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz242
Date:
October, 2019
Fichier:
PDF, 112 KB
english, 2019
File converter
Plus de résultats de recherche
More benefits 
